EXPRESS: Further observations on the behavioral and neural effects of bone marrow stromal cells in rodent pain models by Guo, Wei et al.
Title EXPRESS: Further observations on the behavioral and neuraleffects of bone marrow stromal cells in rodent pain models
Author(s)
Guo, Wei; Chu, Yu Xia; Imai, Satoshi; Yang, Jia Le; Zou,
Shiping; Mohammad, Zaid; Wei, Feng; Dubner, Ronald; Ren,
Ke




© The Author(s) 2016. Creative Commons Non Commercial
CC-BY-NC: This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 3.0 License
(http://www.creativecommons.org/licenses/by-nc/3.0/) which
permits non-commercial use, reproduction and distribution of
the work without further permission provided the original work






Further observations on the behavioral
and neural effects of bone marrow
stromal cells in rodent pain models
Wei Guo, MD, PhD1, Yu-Xia Chu, PhD1,2, Satoshi Imai, PhD1,3,
Jia-Le Yang, PhD1, Shiping Zou, BS1, Zaid Mohammad, BS1,
FengWei, MD, PhD1, Ronald Dubner, DDS, PhD1 and Ke Ren, PhD1
Abstract
Background: Bone marrow stromal cells (BMSCs) have shown potential to treat chronic pain, although much still needs to
be learned about their efficacy and mechanisms of action under different pain conditions. Here, we provide further conver-
gent evidence on the effects of BMSCs in rodent pain models.
Results: In an orofacial pain model involving injury of a tendon of the masseter muscle, BMSCs attenuated behavioral pain
conditions assessed by von Frey filaments and a conditioned place avoidance test in female Sprague-Dawley rats. The
antihyperalgesia of BMSCs in females lasted for <8 weeks, which is shorter than that seen in males. To relate preclinical
findings to human clinical conditions, we used human BMSCs. Human BMSCs (1.5 M cells, i.v.) attenuated mechanical and
thermal hyperalgesia induced by spinal nerve ligation and suppressed spinal nerve ligation-induced aversive behavior, and the
effect persisted through the 8-week observation period. In a trigeminal slice preparation, BMSC-treated and nerve-injured
C57B/L mice showed reduced amplitude and frequency of spontaneous excitatory postsynaptic currents, as well as excita-
tory synaptic currents evoked by electrical stimulation of the trigeminal nerve root, suggesting inhibition of trigeminal
neuronal hyperexcitability and primary afferent input by BMSCs. Finally, we observed that GluN2A (N-methyl-D-aspartate
receptor subunit 2A) tyrosine phosphorylation and protein kinase Cgamma (PKCg) immunoreactivity in rostral ventromedial
medulla was suppressed at 8 weeks after BMSC in tendon-injured rats.
Conclusions: Collectively, the present work adds convergent evidence supporting the use of BMSCs in pain control. As
PKCg activity related to N-methyl-D-aspartate receptor activation is critical in opioid tolerance, these results help to
understand the mechanisms of BMSC-produced long-term antihyperalgesia, which requires opioid receptors in rostral
ventromedial medulla and apparently lacks the development of tolerance.
Keywords
Orofacial pain, tendon ligation, spinal nerve injury, chronic constriction injury, trigeminal neuron, mesenchymal stromal cells
Date received: 10 May 2016; revised: 3 June 2016; accepted: 8 June 2016
Introduction
Studies have shown that bone marrow stromal cells
(BMSCs), a major type of multipotent mesenchymal
stromal (or stem) cells, appear to have potential to
treat chronic pain conditions.1,2 In a randomized,
blinded, placebo-controlled veterinary clinical trial,
autologous adipose-derived mesenchymal stem cells sig-
niﬁcantly improved pain scores in dogs with chronic
osteoarthritis of the hip.3 BMSCs have been shown to
improve tendon injuries in racehorses.4 Recent studies
indicate that ex vivo expanded mesenchymal stem cells
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have pain-relieving properties in preclinical pain models
and do not show adverse side eﬀects.5–13
In a myogenic orofacial pain rat model involving the
ligation injury of the tendon of the masseter muscle,14 we
have shown that intravenous infusion of BMSCs derived
from the rat produced long-term attenuation of mechan-
ical pain hypersensitivity in male rats.9 In the present
study, we aimed to provide further convergent evidence
to support the BMSC-produced antihyperalgesia. We
have extended the observation to female rats and
spinal nerve injury models and used additional measures
of nociception including nociceptive thermal responses,
conditioned place avoidance (CPA), and trigeminal
neuronal synaptic activity. Further, we observed that
the long-term antihyperalgesic eﬀect of BMSCs was
associated with suppression of N-methyl-D-aspartate
(NMDA) receptor 2A subunit (GluN 2A) phosphoryl-
ation in the pain modulatory circuitry.
Methods
Animals and pain models
Sprague-Dawley rats (200–250 g) and C57BL/6 mice
(&20 g) were purchased (Harlan, Indianapolis, IN).
Animals involved in the present study were housed on
the ninth ﬂoor of the University of Maryland School of
Dentistry. The facility is an approved, registered research
site (USDA #MD-R-118) and accredited by Association
for Assessment and Accreditation of Laboratory Animal
Care. Animals were kept under controlled environ-
ment conditions (&22C), relative humidity 40–60%,
12 h/12 h light–dark cycles, and food and water ad lib-
itum. The animals were allowed to acclimate post arrival
for 3–5 days before experiments. They were housed in
cages (2–3 rats and 4–5 mice per cage) with ﬂoors cov-
ered by soft bedding materials to minimize potential
painful contact with a hard surface. The animals’ condi-
tions were monitored continuously throughout the
course of studies, which include body weight, grooming,
locomotion, ambulant activity, and condition of the
wound. The behavioral studies involve stimulation that
produces only momentary additional pain or discomfort
and the rats can escape from the stimuli at any time.
The following three rodent pain models were used: (1)
Tendon ligation (TL) was achieved via an intraoral
approach as described elsewhere.14 Brieﬂy, on the left
intraoral site, a 5-mm long incision was made poster-
ior–anteriorly lateral to the gingivobuccal margin in
the buccal mucosa, beginning immediately next to the
ﬁrst molar. The tendon of the anterior superﬁcial part
of the rat masseter muscle was gently freed and tied with
two chromic gut (4.0) ligatures, 2-mm apart. (2) L5
spinal nerve ligation (SNL) was performed per Kim
and Chung.15 Brieﬂy, the left paraspinal muscles were
separated with a hemostat from the spinous process at
the L4–S2 levels. The L5 spinal nerve was isolated and
tightly ligated with one silicon-treated silk (9.0) suture.
(3) Chronic constriction injury of the infraorbital nerve
(CCI-ION) was performed in mice according to Wei
et al.16 A 5–7mm long incision was made along the left
gingivobuccal margin in the buccal mucosa. The ION is
freed from surrounding connective tissues. At 3–4mm
from the nerve where its branches emerge from the infra-
orbital ﬁssure, the ION was loosely tied with two chro-
mic gut (4.0) ligatures, 2-mm apart. All surgical
procedures were performed under pentobarbital sodium
(20–50mg/kg i.p.) anesthesia. Animals were randomly
assigned to experimental groups. The number of animals
for diﬀerent experimental conditions was determined by
our previous studies and a power analysis.
The vaginal smears of the female rats were taken by a
physiological saline lavage with an eyedropper. The solu-
tion was examined under a microscope for the cell con-
tent of the vaginal canal. The stage of the estrous cycle
was determined by relative frequency of leukocytes, cor-
niﬁed, and nucleated epithelial cells.17
All experiments were carried out in accordance with
the National Institute of Health Guide for the Care and
Use of Laboratory Animals (National Institute of Health
Publications No. 80–23) and approved by the University
of Maryland, Baltimore, Institutional Animal Care and
Use Committee. The report was prepared following the
ARRIVE guidelines.
BMSC procedures
Primary cultures of BMSCs were obtained from donor rats
as described.9,18 The rats were sacriﬁced with CO2, both ends
of the tibiae, femurs, and humerus were cut oﬀ by scissors. A
syringe ﬁtted with an 18-gauge needle was inserted into the
shaft of the bone and bone marrow was ﬂushed out with
culture medium (alpha-modiﬁed Eagle medium, Gibco,
Carlsbad, CA, USA; 10% fetal bovine serum, Hyclone,
Logan, UT, USA). The bone marrow was then mechanically
dissociated and the suspension passed through a 100-m cell
strainer to remove debris. The cells were incubated at 37C
in 5% CO2 in tissue-culture ﬂasks (100 200mm) (Sarstedt,
Nu¨mbrecht, Germany), and non-adherent cells were
removed by replacing the medium. At day 7, when the cul-
tures reached 80% conﬂuence, the cells were washed with
PBS and harvested. The cell numbers were calculated by the
Hemacytometer. For intravenous administration, 1.5 106
cells (1.5M) in 0.2ml PBS were slowly injected into one tail
vein of the anesthetized rat over a 2-minute period using a
22-gauge needle. The property of expanded cells was
assessed by ﬂow cytometry with conventional markers.9
Flow cytometry analyses were performed at the University
of Maryland Greenbaum Cancer Center Shared Flow
Cytometry Facility.
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Cryopreserved human primary BMSCs (hBMSCs)
were purchased (KT-002, RoosterBio, Inc., Frederick,
MD, USA). hBMSCs vial from liquid nitrogen was
immediately thawed in 37C water bath. Cells were
removed from water bath once only a small bit of ice
was remaining. Cells were aseptically transferred into
50-ml centrifuge tube, and 4ml of culture media were
slowly added. Cells were centrifuged 200 g for 10min
and the supernatant was carefully removed without dis-
turbing the pellet. The cells were then resuspended in
45ml of culture media, mixed well, and seeded into
three T75 vessels. After reaching 90% conﬂuence,
the cells were passed into six 10-cm culture plates. The
cells were collected after reaching more than 90% con-
ﬂuence and 1.5M cells infused to the animals.
Behavioral testing
All behavioral tests were conducted under blind condi-
tions. Mechanical sensitivity of the orofacial region was
assessed as described.14,19 A series of calibrated von Frey
ﬁlaments were applied to the skin above the injured
tendon or the corresponding contralateral side. An
active withdrawal of the head from the probing ﬁlament
was deﬁned as a response. Each von Frey ﬁlament was
applied ﬁve times at intervals of 5–10 seconds. The
response frequencies [(number of responses/number of
stimuli) 100%] to a range of von Frey ﬁlament forces
were determined, and a stimulus-response frequency
(S-R) curve was plotted. After a non-linear regression
analysis, an EF50 value, deﬁned as the eﬀective von
Frey ﬁlament force (g) that produces a 50% response
frequency, was derived from the S-R curve (Prism,
GraphPad).20 A leftward shift of the S-R curve, resulting
in a reduction of EF50, occurred after TL or CCI-ION.
This shift of the curve suggests the development of mech-
anical hypersensitivity or presence of mechanical hyper-
algesia and allodynia since there was an increase in
response to suprathreshold stimuli and a decreased
response threshold for nocifensive behavior.
For the hind paw nocifensive behavioral test, an elec-
tronic von Frey unit (EVF3, Bioseb) was used to assess
mechanical sensitivity according to Ren.19 The measure-
ment range of the unit is 0 to 500 g with 0.1 g resolution.
The probe was applied against the lateral edge of the
hind paw with gradually increasing force. The force (g)
that induced paw withdrawal was digitized by the unit
and used as the threshold for mechanical nociception.
Hind paw thermal hyperalgesia was assessed by measur-
ing the latency of paw withdrawal in response to a radi-
ant heat source.21 The paw withdrawal latency (PWL)
was determined by an electronic clock circuit. A 20-s
cutoﬀ was used to prevent tissue damage.
For measurement of CPA behavior,22 animals were
placed within a 40.5 30.5 16 cm Plexiglas chamber
positioned on top of a mesh screen. One half of the
chamber was painted white (light area) and the other
half was painted black (dark area). During behavioral
testing, animals were allowed unrestricted movement
throughout the test chamber for the duration of a
30-min test period. Testing began immediately with
suprathreshold mechanical stimulation (758mN von
Frey monoﬁlament) applied to the facial skin at 15-s
intervals. The mechanical stimulus was applied to the
skin above the injured tendon when the animal was
within the preferred dark area and the facial skin on
the non-injured side when the animal was within the
non-preferred light area of the test chamber. Pre-injury
naı¨ve animals are mechanically stimulated in an identical
manner as the injured groups. Based on the location of
the animal at each 15-s interval, the mean percentage of
time spent in each side of the chamber was calculated for
the entire test period.
Whole-cell patch-clamp recording
The male mouse brain stem was dissected and horizon-
tally sliced at a thickness of 0.4mm. Slices were kept in a
50-ml glass beaker containing carbogenated protective
artiﬁcial cerebrospinal ﬂuid at 33C. After at least a
1-hour recovery, slices were transferred into a recording
chamber and continuously perfused (10–15ml/min) with
oxygenated Krebs’ solution (composition in mM: NaCl
126, NaHCO3 26, glucose 10, KCl 2.5, CaCl2 2, MgCl2
1.2, and NaH2PO4 1.25) at room temperature. We rec-
orded from lamina II neurons of the subnucleus caudalis
of the spinal trigeminal nucleus (Vc). Spontaneous exci-
tatory postsynaptic currents (sEPSCs) were recorded
continuously at a holding potential of 70mV in the
absence of tetrodotoxin. The recording electrode resist-
ance was 7–10M. To block inhibitory transmission,
1mM strychnine sulfate and 10mM bicuculline methio-
dide were included in the superfusate in all experiments.
Whole-cell voltage-clamp recordings were performed
with series resistance compensation using an EPC 10
ampliﬁer.
Western blot
Rats were anesthetized with isoﬂurane (3%) and quickly
decapitated. The brainstem tissue block that included the
rostral ventromedial medulla (RVM) was harvested by
taking punches with a 15-gauge needle. The tissues were
homogenized in solubilization buﬀer (50mM Tris.HCl,
pH 8.0; 150mM NaCl, 1mM EDTA, 1% NP40, 0.5%
deoxycholic acid, 0.1% SDS, 1mM Na3VO4, 1 U/ml
aprotinin, 20 mg/ml leupeptin, 20 mg/ml pepstatin A).
The homogenate was centrifuged at 20,200 g for
10min at 4C. The supernatant was removed.
The protein concentration was determined using a
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detergent-compatible protein assay with a bovine serum
albumin standard. For detecting the immunoreactivity
with near-infrared ﬂuorescence using the Odyssey
Infrared Imaging System (OdysseyCLx, LI-COR,
Lincoln, NE), 50 mg protein samples were denatured by
boiling for 5min and loaded onto 4%–20% Bis-Tris gels
(Invitrogene). After electrophoresis, proteins were trans-
ferred to nitrocellulose membranes. The membranes
were blocked for 1 h with Odyssey Blocking Buﬀer and
then incubated with primary antibodies: anti-phosphotyr
1246-GluN2A antibody (1:1000, #4206, Cell Signaling,
Danvers, MA) and anti-PKCg antibody (1:1000, ab4145,
abcam, Cambridge, MA), diluted in Odyssey Blocking
Buﬀer at 4C overnight, followed by washing with PBS
containing 0.1% Tween 20 (PBST) three times. The
membranes were then incubated for 1 h with
IRDye800CW-conjugated goat anti-rabbit IgG and
IRDye680-conjugated goat anti-mouse IgG secondary
antibodies (LI-COR) diluted in Odyssey Blocking
Buﬀer. The blots were further washed three times with
PBST and rinsed with PBS. Proteins were visualized by
scanning the membrane with 700 - and 800-nm channels.
The loading and blotting of the amount of protein was
veriﬁed by reprobing the membrane with anti-b-actin
and with Coomassie blue staining.
Immunohistochemistry
Rats were deeply anesthetized with pentobarbital sodium
(100mg/kg, i.p.) and perfused transcardially with 4%
paraformaldehyde in 0.1M phosphate buﬀer at pH 7.4.
The brain stem was removed, post-ﬁxed, and transferred
to 25% sucrose (w/v) for cryoprotection. Transverse sec-
tions (20 -mm) were cut with a cryostat. The free-ﬂoating
sections were incubated with relevant antibodies with
1% normal goat sera and 0.3% Triton x-100 overnight
at 4C. After washes in PBS, the sections were incubated
with relevant IgGs conjugated to Cy3 or Cy2 (1:500;
Jackson ImmunoResearch, West Grove, PA) for 4 h at
room temperature or overnight at 4C. Double immuno-
ﬂuorescent staining was performed for PKCg (abcam)
with NeuN (Chemicon) or GluN2A (Santa Cruz).
Following washes, the stained sections were mounted
on gelatin-coated slides and coverslipped with
Vectashield (Vector Laboratories). Slides were examined
with a Nikon ﬂuorescence microscope and images were
captured with a CCD Spot camera. Control sections
were processed with the same method except that the
primary antisera are omitted.
Data analysis
Data are presented as mean (95% conﬁdence interval)
for von Frey ﬁlament force data (EF50s) and
meanSEM for other data. Statistical comparisons
were made by the use of analysis of variance
(ANOVA). For unbalanced sample size, multiple regres-
sions were performed and Type III sum-of-squares was
used to calculate p values (GraphPad Prism). The Tukey
test was performed for post-hoc comparisons. For ani-
mals that were subject to repeated testing, ANOVA with
repeated measures was used. p< 0.05 was considered sig-
niﬁcant for all cases.
Results
BMSC attenuated hyperalgesia in females with tendon
injury
Women exhibit a signiﬁcantly higher prevalence of tem-
poromandibular pain than men.23 However, it is unclear
whether BMSCs produce long-lasting attenuation of
orofacial pain in females as that in males.9 Thus, we
examined the eﬀect of rat BMSCs in female animals in
the TL model.14 The TL rats groomed normally and
displayed normal locomotor activity. They maintained
their weight and explored their environment and inter-
acted with cagemates. BMSCs did not produce adverse
eﬀects on the animals. As shown in Figure 1(a), EF50s of
von Frey ﬁlaments, a measure of mechanical sensitivity,
were signiﬁcantly reduced at 7 days post-TL on the ipsi-
lateral injured side (p< 0.001) compared to the baseline,
indicating the development of mechanical hyperalgesia
and allodynia after TL. Following infusion of BMSCs
(1.5M cells, n¼ 6), the ipsilateral EF50s were signiﬁ-
cantly elevated (Figure 1(a)). The increased EF50s
lasted for at least 28 days post-BMSC. At 56 days post-
BMSC, EF50 showed more variability and the increase
did not reach statistical signiﬁcance. Infusion of culture
medium (n¼ 5) did not have an eﬀect and BMSCs did
not aﬀect EF50 on the contralateral non-injured side
(Figure 1(a)).
Pain involves both sensory discriminative and emo-
tional/aversive components. We also assessed aversive
behavior in a separate set of female rats during persistent
orofacial pain with the CPA behavior test.22 During the
test, rats were placed within a chamber equally divided
into a light and a dark area. Rats normally prefer to stay
in the dark area although they are allowed to move
between the chambers. In TL-treated rats, the injured
side was stimulated with a suprathreshold von Frey ﬁla-
ment while the rat stayed in the dark area (Figure 1(b)).
When the rat moved to the light side, the corresponding
non-injured side was stimulated. Thus, staying in the
preferred dark side was associated with a painful stimu-
lus and the rat was forced to make a decision to remain
there or avoid the painful stimulus. TL induced an
increase in time spent in the light area. For example, in
the BMSC group, rats only spent 11.5 4.3% of time in
the light chamber before injury, but stayed there for
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56.7 1.8% of time at 7 days after TL (Figure 1(b)). At 9
days post-TL, BMSCs (1.5M) were infused i.v. and the
CPA tested again at 7 days after BMSCs (TL-16 days).
BMSC-treated rats spent signiﬁcantly less time
(7.7 2.4%) in the light area of the chamber, compared
to medium-treated rats (67.7 3.6%), suggesting sup-
pression of aversive behavior (Figure 1(b)).
The effect of human BMSCs on neuropathic pain
We next extended our observations to a spinal model of
neuropathic pain with human BMSCs (hBMSCs) treat-
ment. L5 SNL injury was produced in male rats, and
hBMSCs (1.5M cells) were infused at 7 days after
nerve injury when persistent hyperalgesia had developed.
We tested the eﬀect of hBMSCs in rats after spinal nerve
injury on mechanical and thermal nociception. As shown
in Figure 2(a), hBMSC (1.5M cells) signiﬁcantly
increased mechanical nociceptive threshold of the rat
hind paw measured with an electronic von Frey unit,
compared to that before infusion of BMSCs (SNL
7days). The thermal pain hypersensitivity was also sig-
niﬁcantly attenuated as shown by a signiﬁcant increase in
PWL to a noxious thermal stimulus (Figure 2(b)). These
eﬀects persisted over the 8-weeks testing period, similar
to that in the orofacial pain models with rat BMSCs.9
Rat BMSCs also produced antihyperalgesia in the SNL
rats (data not shown). Both hBMSCs and rat BMSCs
also reversed aversive behavior in rats with SNL, as
indicated by a signiﬁcant reduction of time spent in the
light chamber after injury in the CPA test (Figure 2(c)).
The effect of BMSCs on trigeminal neuronal activity
In addition to multiple behavioral endpoints, we exam-
ined the eﬀects of rat BMSCs on trigeminal neuronal
activity. We chose to use an ex vivo trigeminal slice
adult mouse preparation recently adapted in our
lab24,25 since the trigeminal nerve root can be included
for stimulation. A similar preparation of the subnucleus
caudalis of the spinal trigeminal nucleus (Vc) with tri-
geminal nerve root attached is unavailable from the adult
rat. For this mouse preparation, the CCI-ION was pro-
duced.16 We have previously shown that BMSCs attenu-
ated pain hypersensitivity in the CCI-ION model in
rats.9 A total of 12 male mice were used in neuronal
recordings (Naı¨ve: 3, Medium: 3, BMSC: 6). One to
two slices were taken from one animal and one neuron
was recorded from one slice.
At 14 days after CCI-ION, male mice received
BMSCs (1.5M cells) or medium control infusion from
a tail vein. At 1–6 days after BMSCs, we recorded from
lamina II neurons of the Vc (medullary dorsal horn). The
eﬀects of BMSCs were consistent during the ﬁrst week
after BMSC administration, and cells were combined in
each group for analysis. Compared to that from culture
medium-treated mice, the Vc neurons in BMSC-treated
animals showed signiﬁcantly reduced amplitude and
Figure 1. Effect of BMSCs on hyperalgesia in female rats. (a) At 7 days after TL, BMSCs (1.5 M) were infused through a tail vein (arrow).
Compared to culture medium-injected rats, EF50s on the injured ipsilateral (Ipsi) side were increased in BMSC-treated rats, indicating
attenuation of hyperalgesia. BMSCs did not affect EF50 on the non-injured contralateral (Con) side. Error bars are 95% confidence intervals
of EF50. *, p< 0.05, vs. medium. (b) TL-induced aversive behavior and the effects of BMSCs in the conditioned place avoidance (CPA) test
(left). Compared to Pre-TL, the percentage of time rats spent within the light area was increased after TL (7 days). Infusion of BMSCs
resulted in a reduction of TL-induced aversive behavior, indicated by a decrease in time spent in the light chamber (TL-16 days). Error bars
are SEM (***, p< 0.001). ANOVA with post-hoc comparisons.
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frequency of sEPSCs (Figure 3(a), (c), and (d)). In slices
from BMSC-treated mice, naloxone, an opioid receptor
antagonist (1mM), rekindled the frequency of sEPSCs
compared to vehicle treated slices (Figure 4(a), (b), and
(d)) without an eﬀect on the amplitude of sEPSCs
(Figure 4(a), (c), and (e)), suggesting a presynaptic
action of BMSC-induced endogenous opioids.9,26 The
eﬀect of naloxone was consistent with behavioral obser-
vation and suggests the involvement of endogenous opi-
oids in BMSC’s antihyperalgesia.
Electrical stimulation of the trigeminal nerve root at
suprathreshold intensity (0.2 mA, 0.1ms pulse) after
depolarizing the cell to þ40mV evoked NMDA recep-
tor-mediated synaptic currents or eEPSCs in lamina II
neurons of Vc (Figure 3(b)). The evoked current was
induced in the presence of CNQX (10M), an AMPA/
kainate receptor antagonist, strychnine (1M), a glycine
receptor antagonist, and bicuculline (10M), a GABAA
receptor antagonist, but was abolished when AP-5
(0.02–1mM), an NMDA receptor antagonist, or tetro-
dotoxin (1m), a sodium channel blocker, was added to
the bath. Compared to naı¨ve mice, the NMDA receptor-
mediated eEPSCs were increased in mice (14 days after
CCI-ION) receiving the medium treatment, but returned
Figure 2. Effects of human BMSCs (hBMSC) on neuropathic pain. (a) L5 spinal nerve injury (SNL) was produced in male rats. Mechanical
sensitivity was assessed with an electronic von Frey unit. Primary hBMSCs were infused i.v. at 0.2 ml with 1.5 M cells at 7 days after SNL.
Compared to medium control, the mechanical nocifensive response threshold (Ipsi) of BMSC-treated rats was increased, indicating
attenuation of hyperalgesia. (b) Thermal nocifensive responses, expressed by paw withdrawal latency (PWL) to a noxious thermal stimulus,
of SNL rats were inhibited in hBMSC-treated rats, indicating attenuation of thermal hyperalgesia. ***, p< 0.001, versus Medium, ANOVA
with post-hoc comparisons. (c) The effects of hBMSCs and rat BMSCs (rBMSCs) on SNL-induced aversive behavior. Compared to naı¨ve
rats, the percentage of time spent within the light area was increased after SNL in medium-treated rats. Infusion of BMSCs resulted in a
reduction of SNL-induced aversive behaviour, indicated by a decrease in time spent in the light chamber. ***, p< 0.001, versus Medium.
###, p< 0.001, versus naı¨ve. Error bars are SEM.
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to the naı¨ve level in BMSC-treated animals (Figure 3(b),
3(e)). These results suggest inhibition of trigeminal neur-
onal hyperexcitability and primary nociceptive aﬀerent
input at the Vc level after BMSC treatment.
The effect of BMSCs on NMDA receptor phosphory-
lation and protein kinase Cgamma (PKC)
Our previous studies indicate that endogenous opioid
receptors in the RVM, an important site of the pain
modulatory circuitry, contribute to BMSC-produced
long-term antihyperalgesia.9 While tolerance to endogen-
ous opioids may develop after repeated opioid receptor
activation,27 surprisingly, analgesia tolerance did not
develop after infusion of BMSCs.9 Since the NMDA
receptor is involved in the development of opiate toler-
ance,28,29 we examined the eﬀect of BMSCs on NMDA
receptor activity in the RVM. TL was produced in male
rats and BMSCs (1.5M) was infused i.v. at 7 days post
TL. RVM tissues were collected at 1 week and 8 weeks
Figure 3. Effects of BMSCs on synaptic activity of trigeminal neurons. Whole cell patch clamp recordings were performed at 1 to 6 days
after infusion of rat BMSCs from horizontal slices of the Vc with attached trigeminal nerve root prepared from adult mouse (5–8 weeks).
(a) Examples of spontaneous excitatory postsynaptic current (sEPSC). (b) NMDA receptor-mediated synaptic current, or eEPSC, was
obtained by electrical stimulation of the nerve root at suprathreshold intensity (0.2 mA, 0.1 ms pulse) after depolarizing the cell to þ40 mV.
The evoked current was induced in the presence of CNQX (10 M), strychnine (1 M), and bicuculline (10 M), but was abolished when AP-5
(0.02–1 mM) or tetrodotoxin (1 m) was added to the bath. The eEPSC was increased in CCI mice receiving medium but significantly
reduced in BMSC-treated animals. Mg2þ was absent in the external solution. (c to e) Summary of the effect of BMSCs on sEPSC amplitude
(C), frequency (D), and eEPSC (E). Holding potential ¼ 70 mV. Number in the bars indicates the number of neurons in each group.
**, p< 0.01, ***, p< 0.001, versus naı¨ve; #, p< 0.05, ##, p< 0.01, versus CCI. ANOVA with post-hoc comparisons.
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after BMSC infusion. We used 20-passage BMSCs as a
control since they did not produce antihyperalgesia.9
We have shown that the GluN2A subunit of the
NMDA receptor in the RVM is important for descend-
ing pain facilitation.30 Using an antibody against phos-
photyrosine 1246 of the GluN2A, compared to
20-passage BMSCs (248 51% of naive), we observed
that GluN2A tyrosine phosphorylation (pGluN2A) in
the RVM tissue was suppressed at 8 weeks (96 29%
of naive) after primary rat BMSC treatment in TL rats
(Figure 5(a)). There is evidence that PKCg activity
related to NMDA receptor activation plays critical role
in opioid tolerance.31,32 Consistently, PKCg expression
in the RVM was also decreased at 8 weeks (133 46%
of naive) after primary BMSC treatment compared to
20-passage BMSC-treated rats (289 52% of naive)
(Figure 5(b)). Double immunoﬂuorescent staining showed
that PKCg-like immunoreactivity colocalized with NeuN,
a neuronal marker, and GluN2A (Figure 5(c)). These
results suggest that BMSC-produced long-term antihyper-
algesia involve an eﬀect on NMDA receptors and signaling
pathways associated with opioid tolerance.
Discussion
Proper treatment of chronic pain conditions continues to
be an unmet challenge. Recent studies have shown
potential of mesenchymal stromal cells for the manage-
ment of chronic pain, although much still needs to be
learned about their eﬃcacy and mechanisms of action in
the CNS under diﬀerent pain conditions. The present
work provides further convergent evidence that favor
Figure 4. Effect of naloxone on sEPSCs. (a) Examples of sEPSC recordings. (b, c) Cumulative fraction curves of sEPSC inter-event intervals
(b) and amplitude (c). Note a left-ward shift of the inter-event interval curve in naloxone-treated mice, suggesting a reduction in the event
interval or an increase in sEPSC frequency. (d, e) Summary of the effect of naloxone on sEPSC frequency (d) and amplitude (e) in CCI mice
treated with BMSCs. Number in the bars indicates the number of neurons in each group. ***, p< 0.001, versus vehicle, Student t-test.
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the use of mesenchymal stromal cells for pain relief. We
show that both rat and human BMSCs, a major type of
mesenchymal stromal cells, produced long-lasting pain
attenuation and inhibited trigeminal neuronal hyperex-
citability in rodent models of persistent pain and that
BMSCs suppressed NMDA receptor phosphorylation
and PKC levels in the RVM pain modulatory circuitry.
We recently developed a myogenic orofacial pain
model involving a tendon of the masseter muscle.14
The model is particularly useful in studying the chron-
icity of pain associated with temporomandibular joint
disorders. In the present study, we used this model in
female rats to evaluate the eﬀect of BMSCs in order to
compare it to the eﬀects in male rats conducted in a
previous study.9 The results showed reversal of sensory
and emotional pain hypersensitivity in these rats, consist-
ent with previous report.9 The antihyperalgesia of
BMSCs is unlikely related to an eﬀect on motor behavior
as shown in previous reports.8,9,12 These results further
demonstrate that a single infusion of BMSCs produced
long-lasting antihyperalgesia. In the same TL model,
analgesia produced by a single dose of morphine and
duloxetine, two commonly used analgesics, waned in
less than two hours.14 The long-lasting pain relieving
eﬀect of BMSCs have also been shown in other stu-
dies12,33 and the underlying cellular mechanisms require
further investigation.
We noticed that the increase in EF50s in female rats
only reached statistical signiﬁcance at the ﬁrst four weeks
after the BMSC treatment. Thus, the pain-attenuating
Figure 5. Effect of BMSC on NMDA receptor phosphorylation and PKCg in RVM. (a) Total proteins from RVM tissues were isolated and
GluN2A (NR2A) subunit tyrosine phosphorylation was determined with anti-phosphotyrosine 1246 GluN2A (pGluN2A). At 8 weeks after
primary (PRI) BMSC treatment, pGluN2A was increased in 20 P-BMSC samples (**, p< 0.01, vs. navie, n¼ 3). The BMSC treatment led to a
return of the P-GluN2A to the naı¨ve level (##, p< 0.01, vs. 20 P/8 weeks). There was a trend for increase in pGluN2A at 1 week after
BMSC treatment, which was likely an effect of injury. (b) The levels of PKCg were reduced in PRI BMSC-treated rats at the 8-week time
point (#, p< 0.05, vs. 20 P/8 weeks). b-actin was a loading control. N¼ 3/group, ANOVA with post-hoc comparisons. (c) Localization of
PKCg- and GluN2A-like immunoreactivity in RVM neurons. Brainstem tissue sections were processed for PKCg and GluN2A double
immunofluorescence staining. PKCg immunoreactivity (red, Cy3) is colocalized with NeuN (green, Cy2). Overlap of images of the left and
middle columns reveals double fluorescence (right, yellow/orange). Arrows indicate examples of double-labeled neurons. Scale¼ 0.25 mm.
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eﬀect of BMSCs in the female rats appeared to last
shorter (<8 weeks) compared to that in male rats (up
to ﬁve months).9 Considering the involvement of RVM
mu-opioid receptors in BMSC-produced antihyperalge-
sia,9 this result is unexpected as female rats have been
shown to be more sensitive to the mu-opioid agonist
injected into the periaqueductal gray.34 Although we
monitored the estrous status of the rats, we did not sep-
arate female rats based on the estrous status since there
were no signiﬁcant cycle-related diﬀerences in baseline
responses as we showed previously.35 In fact, ‘‘there is
no good meta-evidence that the cyclicity of female
rodents is a strong systematic modulator of pain sensi-
tivity’’.36 Thus, the female gonadal hormonal status is
unlikely a factor that interrupts BMSC-produced eﬀect.
Considering diﬀerent involvement of immune cells in
pain in males and females,37 it is worth pursuing that
whether there is sex diﬀerence in BMSC-produced
immune regulation related to their pain relieving eﬀect.
We show that post-injury treatment with hBMSCs
produced long-lasting antihyperalgesia in rats with
spinal nerve injury similar to that of trigeminal tissue
or nerve injury.9 Both thermal and mechanical hypersen-
sitivity as well as aversive behavior were attenuated after
systemic infusion of hBMSCs. The use of human cells is
important for relating preclinical ﬁndings to clinical con-
ditions. Only a few preclinical studies have reported
pain-attenuating eﬀect of hBMSCs7,8 or human adi-
pose-derived mesenchymal stem cells [10; also see 1 for
a review). The antihyperalgesia of hBMSCs seen in the
present study seems more prominent compared to other
reports,8,10 although a direct comparison is not justiﬁed
due to diﬀerent species (rat vs. mouse), nerve injury
models (SNL vs. spared nerve injury and CCI), and the
use of primary versus passage cells. In contrast to
hBMSCs and adipose-derived cells, human umbilical
cord blood-derived mesenchymal stem cells did not pro-
duce a signiﬁcant eﬀect on pain hypersensitivity after
spinal cord injury in mice,38 suggesting phenotypic dif-
ferences between diﬀerent mesenchymal stem cell types.
The available evidence favors the use of primary
hBMSCs or adipose-derived mesenchymal stem cells in
pain relief.
Utilizing an ex vivo Vc slice preparation from adult
mice, we show that BMSCs inhibited hyperexcitability of
trigeminal medullary dorsal horn neurons after nerve
injury, which has not been observed previously. In
slices from BMSC-treated mice, nerve injury-induced
increases in frequency and amplitude of sEPSCs were
signiﬁcantly reduced, suggesting reduced presynaptic
glutamate release and postsynaptic hyperexcitaility.39
Further, NMDA receptor-mediated eEPSC was
enhanced in CCI-ION mice but this increase was abol-
ished after treatment with BMSCs, supporting that
BMSCs produce a decrease of primary aﬀerent
nociceptive input. The inhibition of trigeminal neuronal
activity is consistent with the pain-relieving eﬀect of
BMSCs. Chen et al.12 show that BMSC-produced anti-
hyperalgesia involves transforming growth factor beta1
(TGFb1) and direct application of TGFb inhibited
sEPSC of spinal neurons. Our results also suggest that
BMSC may engage endogenous opioid receptors to con-
trol nociceptive transmission in the medullary dorsal
horn. Similar to an eﬀect on behavioral hyperalgesia,9
naloxone rekindled sEPSC frequency in BMSC-treated
mice. This electrophysiological evidence not only com-
plements behavioral measure of nociception but also
demonstrates that BMSC exert a selective eﬀect on sen-
sory transmission pathways.
We ﬁnally examined the eﬀect of BMSCs on NMDA
receptor activity in RVM. We show that BMSCs sup-
pressed GluN2A phosphorylation in RVM at a later
(8 weeks) but not early (1 week) time point of treatment.
Thus, the later, but not early eﬀect of BMSCs involves an
action on NMDA receptors. The NMDA receptor is a
major mediator of central sensitization and hyperalgesia,
while it also is involved in the development of opiate tol-
erance.28,29 Chronic morphine treatment upregulates
NMDA receptor subunit expression.40 Since RVM opioid
receptors are required for BMSC-produced antihyperalge-
sia and the analgesic tolerance does not develop as
suggested by the long-term eﬀect of BMSCs,9 the late sup-
pression of NMDA receptor activity would be consistent
with inhibition of the development of opioid tolerance.
Interestingly, mesenchymal stem cells inhibit NMDA
receptor expression and protect against glutamate excito-
toxicity in culture.41 Related to this, amniotic epithelial
stem cells attenuated GluN1 (NR1) subunit phosphoryl-
ation and alleviated mechanical allodynia after spinal
cord injury in rats.38 PKCg activity related to NMDA
receptor activation is essential for the development of
opioid tolerance.31,32 We show that PKCg expression in
RVM was also decreased at 8w after BMSC treatment.
These results suggest that signaling pathways related to
the development of opioid tolerance, particularly at the
late phase of BMSC-produced antihyperalgesia, are inter-
rupted in BMSC-treated animals. These results suggest a
promising analgesic proﬁle of BMSC: to inhibit NMDA
receptor activation and promote opioid analgesia while
suppressing the development of tolerance.
The present work adds convergent evidence to the
growing preclinical literature that support the use of
BMSCs in pain control. It is interesting that BMSCs
produced similar antihyperalgesic eﬀect under diverse
conditions that potentially involve multiple mechanisms.
Future studies will identify cellular mechanisms that are
crucial in BMSCs’ pain relieving eﬀect. We show that
BMSCs have antihyperalgesic eﬃcacy in a number of
animal persistent pain models by multiple endpoints.
Clinical studies have also been promising. In a proof of
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concept clinical study, adipose mesenchymal stromal
cells reduced pain in females with trigeminal pain.42 A
single local administration of autologous bone marrow
concentrate cells, mainly mesenchymal stromal cells, sig-
niﬁcantly reduced lumbar discogenic pain up to 12
months.33 Since BMSCs are easy to isolate and expand
ex vivo and relatively safe in clinical use,43 their thera-
peutic use may provide a novel direction in the manage-
ment of chronic pain conditions.
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